Document is current

Article History

Received: 7 May 2025

Revised: 14 October 2025

Accepted: 3 November 2025

First Online: 6 January 2026

Compliance with ethical standards

:

: The scientific guarantor of this publication is T.G.O.

: The authors of this manuscript declare relationships with the following companies: T.G.O. has been a consultant for Sonae and Guidepoint, has received fees as a speaker from Eisai and conference fees covered from Roche and Lilly. M.V. has received fees as a speaker from Eisai. Advisory board member for the Dutch Alzheimer Foundation (Alzheimer Nederland). G.B.F. has received consulting fees from: Biogen, Diadem, Roche; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from: Biogen, Roche, Novo Nordisk, and GE HealthCare (all of these through his institution). R.W.: Advisory board member for EISAI, Lilly, and Bayer. R.W. has received speaker honorarium from Lilly and Bayer. F.B.: Steering committee or Data Safety Monitoring Board member for Biogen, Merck, Eisai, and Prothena. Advisory board member for Combinostics, Scottish Brain Sciences, Alzheimer Europe. Consultant for Roche, Celltrion, Rewind Therapeutics, Merck, and Bracco. Research agreements with ADDI, Merck, Biogen, GE Healthcare, and Roche. Co-founder and shareholder of Queen Square Analytics LTD.

: No complex statistical methods were necessary for this paper.

: Written informed consent was not required for this study because the results presented were based on a voluntary online survey.

: The questionnaire was reviewed and approved by the ESNR and EAN scientific panels.

: Not applicable.

: